BASF and Bota launch SkinNexus Collag3n, AI-developed human-identical Collagen III
- BASF is commercializing SkinNexus™ Collag3n, a 100% human-identical recombinant Collagen III fragment produced by yeast fermentation.
- Bota’s Physical AI-driven biofoundry screened over 2,000 collagen fragments while candidate evaluation ran alongside industrial feasibility validation.
- In 3D dermis models the ingredient increased Collagen I by 48%, Collagen III by 82% and Collagen V by 71%.
- Clinical trials in women aged 53–70 showed improvements in sagging and wrinkle appearance after four weeks, outperforming a collagen benchmark used at ten times the concentration.
Product and launch
BASF and Bota Biosciences announced SkinNexus™ Collag3n, a recombinant Collagen III fragment with a 100% human-identical sequence, commercialized by BASF for the personal care market. The ingredient debuted at in-cosmetics Global in April 2026.
Discovery and development
The collaboration combined Bota’s Physical AI-driven biofoundry capabilities with BASF’s cosmetic actives expertise. Partners screened more than 2,000 collagen fragments and ran candidate evaluation in parallel with industrial feasibility validation to bridge discovery and production.
Manufacturing
SkinNexus™ Collag3n is produced by yeast fermentation and positioned as a vegan recombinant fragment suitable for scale-up and commercial supply chains.
Efficacy data
In 3D dermis models the fragment increased Collagen I by 48%, Collagen III by 82% and Collagen V by 71%. Clinical trials in women aged 53–70 reported visible improvements in sagging and wrinkle appearance after four weeks, with results outperforming a collagen benchmark applied at ten times the concentration.
Source: BASF
